Benzinga | Nov 15, 2021 11:07AM EST

Bionano Genomics Announces Extensive Lineup Of Content To Be Presented At The Annual Meeting Of The Association For Molecular Pathology Featuring Optical Genome Mapping Across A Broad Range Of Clinical Research Applications

Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) and provider of industry-leading data interpretation solutions for next-generation sequencing (NGS) and microarrays, today announced the lineup of content scheduled to be presented at the annual meeting of the Association for Molecular Pathology (AMP). The content is expected to include an oral platform presentation by Dr. Ravi Kolhe at Augusta Universty, six poster presentations, a corporate workshop and an innovation spotlight. The presentations this year span a wide range of applications, including prenatal analysis, genetic disease, hematological malignancies, solid tumor and advances in the OGM technique for detecting more clinically relevant variants, including absence of heterozygosity (AOH) and allelic imbalance. The AMP conference is being held virtually starting today, Monday, November 15 and goes until Friday, November 19, 2021.



Bionano's corporate workshop on Thursday, November 18 from 9:00am - 9:50am EST is planned to feature presentations from Dan Saul (BioDiscovery), Dr. Alex Hastie (Bionano), and Dr. Gordana Raca (Children's Hospital LA), where they'll highlight the potential advantages of combining data from OGM and next-generation sequencing (NGS) to obtain the most comprehensive view of genome variation available.

The innovation spotlight will feature presentations from Dr. Soheil Shams (CIO), Dr. Alka Chaubey (CMO) and Dr. Adrian Dubuc from Brigham & Women's Hospital and Harvard Medical School. The content for the spotlight will cover Bionano's efforts in building a cancer knowledgebase for interpreting variants faster, the power of combining OGM and NGS data to reveal significantly more clinically relevant variants than with NGS alone and an illustration of an application of OGM as an alternative to karyotyping and FISH for revealing complex, clinically relevant structural variants in an aggressive leukemia/lymphoma subject.